Endometrium adenocarcinoma

Summary

Endometrium adenocarcinoma (MONDO:0005461) is a disease (an umbrella term covering 9 Mondo subtypes) with 2 cohort genes and 61 clinical trials. Molecularly, MTOR S2215Y confers sensitivity to Sirolimus in Endometrial Adenocarcinoma (CIViC Level D); 1 further subtype–drug associations are mapped below. Top therapeutic interventions include capivasertib, ixabepilone, and megestrol acetate.

At a glance

• Umbrella term: 9 Mondo subtypes
• Cohort genes: 2
• Clinical trials: 61
• Precision-medicine evidence (CIViC): 2 subtype–drug associations

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	endometrium adenocarcinoma
Mondo ID	MONDO:0005461
EFO	EFO:0005232
DOID	DOID:2870
NCIT	C7359
UMLS	C1153706
MedGen	218862
Anatomy (UBERON)	UBERON:0001295
Is cancer (heuristic)	no

Also known as: adenocarcinoma of endometrium · adenocarcinoma of the endometrium · adenocarcinoma, endometrial, malignant · endometrial adenocarcinoma · endometrioid adenoma or carcinoma NOS (morphologic abnormality) · endometrioid adenomas and carcinomas (morphologic abnormality) · endometrioid carcinoma of endometrium · endometrium adenocarcinoma

Data availability: 65 cell lines.

Disease family

An umbrella term covering 9 Mondo subtypes.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › uterine cancer › uterine carcinoma › endometrial carcinoma › endometrium adenocarcinoma

Related subtypes (6): uterine corpus endometrial carcinoma, endometrial transitional cell carcinoma, endometrium carcinoma in situ, endometrial small cell carcinoma, endometrial squamous cell carcinoma, endometrial undifferentiated carcinoma

Subtypes (9): endometrial mucinous adenocarcinoma, villoglandular endometrial endometrioid adenocarcinoma, oxyphilic endometrial endometrioid adenocarcinoma, secretory uterine corpus endometrioid adenocarcinoma, mucin-rich endometrial endometrioid adenocarcinoma, endometrial endometrioid adenocarcinoma with spindled epithelial cells, endometrial mixed adenocarcinoma, endometrial clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 24 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
TP53	Orphanet:1333	Familial pancreatic carcinoma
TP53	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
TP53	Orphanet:1501	Adrenocortical carcinoma
TP53	Orphanet:210159	Adult hepatocellular carcinoma
TP53	Orphanet:251576	Gliosarcoma
TP53	Orphanet:251579	Giant cell glioblastoma
TP53	Orphanet:251899	Choroid plexus carcinoma
TP53	Orphanet:2807	Papilloma of choroid plexus
TP53	Orphanet:293199	Pleomorphic rhabdomyosarcoma
TP53	Orphanet:3318	Essential thrombocythemia
TP53	Orphanet:524	Li-Fraumeni syndrome
TP53	Orphanet:52688	Myelodysplastic syndrome
TP53	Orphanet:585909	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
TP53	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
TP53	Orphanet:668	Osteosarcoma
TP53	Orphanet:67038	B-cell chronic lymphocytic leukemia
TP53	Orphanet:70573	Small cell lung cancer
TP53	Orphanet:96253	Cushing disease
TP53	Orphanet:99756	Alveolar rhabdomyosarcoma
TP53	Orphanet:99757	Embryonal rhabdomyosarcoma
MTOR	Orphanet:269001	Isolated focal cortical dysplasia type IIa
MTOR	Orphanet:269008	Isolated focal cortical dysplasia type IIb
MTOR	Orphanet:457485	Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome
MTOR	Orphanet:99802	Hemimegalencephaly

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
TP53	HGNC:11998	ENSG00000141510	P04637	Cellular tumor antigen p53	civic_evidence
MTOR	HGNC:3942	ENSG00000198793	P42345	Serine/threonine-protein kinase mTOR	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
TP53	Cellular tumor antigen p53	Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence.
MTOR	Serine/threonine-protein kinase mTOR	Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals.

Protein-family classification

Druggable: 1 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.5

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	13.9×	0.142
Transcription factor	1	4.1×	0.228

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
TP53	Transcription factor	no		p53_tumour_suppressor, p53-like_TF_DNA-bd_sf, p53_tetrameristn
MTOR	Kinase	yes		PI3/4_kinase_cat_dom, PIK-rel_kinase_FAT, FATC_dom

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
ganglionic eminence	1
tendon of biceps brachii	1
ventricular zone	1
cerebellar hemisphere	1
primordial germ cell in gonad	1
right hemisphere of cerebellum	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
TP53	223	ubiquitous	marker	ventricular zone, ganglionic eminence, tendon of biceps brachii
MTOR	207	ubiquitous	marker	primordial germ cell in gonad, right hemisphere of cerebellum, cerebellar hemisphere

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
TP53	22,736
MTOR	9,490

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
TP53	P04637	313
MTOR	P42345	70

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 84. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Regulation of TP53 Degradation	2	292.8×	1e-03	TP53, MTOR
Regulation of PTEN gene transcription	2	178.4×	0.001	TP53, MTOR
TP53 Regulates Metabolic Genes	2	129.8×	0.002	TP53, MTOR
Loss of function of TP53 in cancer due to loss of tetramerization ability	1	5710.0×	0.004	TP53
Regulation of TP53 Expression	1	2855.0×	0.006	TP53
Transcriptional activation of cell cycle inhibitor p21	1	1427.5×	0.010	TP53
Activation of NOXA and translocation to mitochondria	1	951.7×	0.012	TP53
RUNX3 regulates CDKN1A transcription	1	815.7×	0.012	TP53
PI5P Regulates TP53 Acetylation	1	634.4×	0.012	TP53
Activation of PUMA and translocation to mitochondria	1	571.0×	0.012	TP53
TP53 Regulates Transcription of Caspase Activators and Caspases	1	475.8×	0.012	TP53
TP53 Regulates Transcription of Death Receptors and Ligands	1	475.8×	0.012	TP53
Urea cycle	1	439.2×	0.012	TP53
Regulation of TP53 Activity through Association with Co-factors	1	407.9×	0.012	TP53
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	1	380.7×	0.012	TP53
Stabilization of p53	1	380.7×	0.012	TP53
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	1	356.9×	0.012	TP53
Dengue virus modulates apoptosis	1	356.9×	0.012	MTOR
Formation of Senescence-Associated Heterochromatin Foci (SAHF)	1	335.9×	0.012	TP53
Zygotic genome activation (ZGA)	1	335.9×	0.012	TP53
Regulation of NF-kappa B signaling	1	317.2×	0.012	TP53
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	1	300.5×	0.012	TP53
SUMOylation of transcription factors	1	285.5×	0.012	TP53
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	1	271.9×	0.012	TP53
Regulation of TP53 Activity through Methylation	1	271.9×	0.012	TP53
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain	1	259.6×	0.012	TP53
Regulation of TP53 Expression and Degradation	1	259.6×	0.012	MTOR
mTORC1-mediated signalling	1	237.9×	0.012	MTOR
Regulation of TP53 Activity through Acetylation	1	228.4×	0.012	TP53
Regulation of T cell activation by CD28 family	1	211.5×	0.012	MTOR

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
negative regulation of helicase activity	1	8426.0×	0.003	TP53
positive regulation of SCF-dependent proteasomal ubiquitin-dependent catabolic process	1	8426.0×	0.003	MTOR
cellular response to actinomycin D	1	8426.0×	0.003	TP53
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	1	8426.0×	0.003	TP53
negative regulation of G1 to G0 transition	1	8426.0×	0.003	TP53
positive regulation of mitochondrial membrane permeability	1	4213.0×	0.003	TP53
oligodendrocyte apoptotic process	1	4213.0×	0.003	TP53
negative regulation of glucose catabolic process to lactate via pyruvate	1	4213.0×	0.003	TP53
regulation of locomotor rhythm	1	4213.0×	0.003	MTOR
positive regulation of cytoplasmic translational initiation	1	4213.0×	0.003	MTOR
negative regulation of pentose-phosphate shunt	1	4213.0×	0.003	TP53
multicellular organism growth	2	137.0×	0.003	TP53, MTOR
cellular response to hypoxia	2	121.2×	0.003	TP53, MTOR
protein stabilization	2	66.9×	0.003	TP53, MTOR
obsolete homolactic fermentation	1	2808.7×	0.003	TP53
signal transduction by p53 class mediator	1	2808.7×	0.003	TP53
negative regulation of miRNA processing	1	2808.7×	0.003	TP53
intrinsic apoptotic signaling pathway in response to hypoxia	1	2808.7×	0.003	TP53
regulation of fibroblast apoptotic process	1	2808.7×	0.003	TP53
T-helper 1 cell lineage commitment	1	2106.5×	0.003	MTOR
T cell proliferation involved in immune response	1	2106.5×	0.003	TP53
positive regulation of programmed necrotic cell death	1	2106.5×	0.003	TP53
oxidative stress-induced premature senescence	1	2106.5×	0.003	TP53
negative regulation of lysosome organization	1	2106.5×	0.003	MTOR
positive regulation of pentose-phosphate shunt	1	2106.5×	0.003	MTOR
B cell lineage commitment	1	1685.2×	0.003	TP53
T cell lineage commitment	1	1685.2×	0.003	TP53
mRNA transcription	1	1685.2×	0.003	TP53
positive regulation of RNA polymerase II transcription preinitiation complex assembly	1	1685.2×	0.003	TP53
cellular response to methionine	1	1685.2×	0.003	MTOR

Therapeutics

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 0

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
TP53	NITROFURANTOIN
MTOR	SALMETEROL XINAFOATE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
TP53	196	4
MTOR	164	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53
NABUMETONE	4	TP53
SALMETEROL XINAFOATE	4	MTOR, TP53
AMIODARONE HYDROCHLORIDE	4	TP53
FURAZOLIDONE	4	TP53
AMOXAPINE	4	MTOR, TP53
RALOXIFENE HYDROCHLORIDE	4	TP53
NICARDIPINE HYDROCHLORIDE	4	TP53
SULCONAZOLE NITRATE	4	TP53
PYRITHIONE ZINC	4	TP53
LACTIC ACID	4	TP53
OXYMETHOLONE	4	TP53
CHLOROXINE	4	TP53
PROPIOLACTONE	4	TP53
CLOMIPRAMINE HYDROCHLORIDE	4	TP53
PHENYL AMINOSALICYLATE	4	TP53
THIORIDAZINE HYDROCHLORIDE	4	TP53
AMITRIPTYLINE HYDROCHLORIDE	4	TP53
ETHOPROPAZINE HYDROCHLORIDE	4	TP53
MECHLORETHAMINE HYDROCHLORIDE	4	TP53
ECONAZOLE NITRATE	4	TP53
TRIFLUPROMAZINE HYDROCHLORIDE	4	TP53
PROCHLORPERAZINE EDISYLATE	4	TP53
DEQUALINIUM CHLORIDE	4	TP53

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
MTOR	1,375	Binding:1335, Functional:37, ADMET:2, Toxicity:1
TP53	869	Binding:775, ADMET:83, Functional:10, Toxicity:1

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
TP53	869
MTOR	1,375

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53
NABUMETONE	4	TP53
SALMETEROL XINAFOATE	4	MTOR, TP53
AMIODARONE HYDROCHLORIDE	4	TP53
FURAZOLIDONE	4	TP53
AMOXAPINE	4	MTOR, TP53
RALOXIFENE HYDROCHLORIDE	4	TP53
NICARDIPINE HYDROCHLORIDE	4	TP53
SULCONAZOLE NITRATE	4	TP53
PYRITHIONE ZINC	4	TP53
LACTIC ACID	4	TP53
OXYMETHOLONE	4	TP53
CHLOROXINE	4	TP53
PROPIOLACTONE	4	TP53
CLOMIPRAMINE HYDROCHLORIDE	4	TP53
PHENYL AMINOSALICYLATE	4	TP53
THIORIDAZINE HYDROCHLORIDE	4	TP53
AMITRIPTYLINE HYDROCHLORIDE	4	TP53
ETHOPROPAZINE HYDROCHLORIDE	4	TP53
MECHLORETHAMINE HYDROCHLORIDE	4	TP53
ECONAZOLE NITRATE	4	TP53
TRIFLUPROMAZINE HYDROCHLORIDE	4	TP53
PROCHLORPERAZINE EDISYLATE	4	TP53
DEQUALINIUM CHLORIDE	4	TP53

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	TP53, MTOR
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 61.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	32
Not specified	12
PHASE1	9
PHASE3	3
PHASE1/PHASE2	3
PHASE4	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03164590	PHASE4	COMPLETED	Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines
NCT03914612	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT00002706	PHASE3	COMPLETED	Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus
NCT00006011	PHASE3	COMPLETED	Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT02065687	PHASE2/PHASE3	UNKNOWN	Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
NCT00977574	PHASE2	ACTIVE_NOT_RECRUITING	Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT03660826	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
NCT04106414	PHASE2	ACTIVE_NOT_RECRUITING	Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
NCT04719273	PHASE2	ACTIVE_NOT_RECRUITING	Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
NCT05112601	PHASE2	RECRUITING	Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT05548296	PHASE2	RECRUITING	A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05824481	PHASE2	ACTIVE_NOT_RECRUITING	Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
NCT06066216	PHASE2	NOT_YET_RECRUITING	Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer
NCT06399757	PHASE1/PHASE2	RECRUITING	A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
NCT06917092	PHASE2	RECRUITING	QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
NCT00006089	PHASE2	COMPLETED	Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT00025467	PHASE2	COMPLETED	Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00064025	PHASE2	COMPLETED	Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
NCT00072176	PHASE2	COMPLETED	Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
NCT00095979	PHASE2	COMPLETED	Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00478426	PHASE2	COMPLETED	Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
NCT00820898	PHASE2	COMPLETED	Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00888173	PHASE2	COMPLETED	Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01005329	PHASE2	COMPLETED	Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
NCT01011933	PHASE2	COMPLETED	Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01041027	PHASE2	TERMINATED	Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer
NCT01132820	PHASE2	COMPLETED	Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01210222	PHASE2	COMPLETED	Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT01225887	PHASE2	COMPLETED	Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01307631	PHASE2	COMPLETED	Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
NCT01642082	PHASE2	COMPLETED	Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01877564	PHASE2	COMPLETED	A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
NCT01943058	PHASE2	WITHDRAWN	Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
NCT01968317	PHASE2	COMPLETED	Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
NCT02549209	PHASE2	COMPLETED	Pembro/Carbo/Taxol in Endometrial Cancer
NCT03221400	PHASE1/PHASE2	UNKNOWN	PEN-866 in Patients With Advanced Solid Malignancies
NCT03540407	PHASE2	COMPLETED	Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.
NCT03643510	PHASE2	COMPLETED	Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
NCT03836157	PHASE2	WITHDRAWN	Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
NCT05001282	PHASE1/PHASE2	TERMINATED	A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CAPIVASERTIB	4	2
IXABEPILONE	4	2
MEGESTROL ACETATE	4	2
TEMSIROLIMUS	4	2
ABEMACICLIB	4	1
BUPIVACAINE	4	1
COPANLISIB	4	1
DURVALUMAB	4	1
FILGRASTIM	4	1
LURBINECTEDIN	4	1
MEDROXYPROGESTERONE ACETATE	4	1
METFORMIN	4	1
MIRVETUXIMAB SORAVTANSINE	4	1
NINTEDANIB	4	1
NIRAPARIB	4	1
PACLITAXEL	4	1
PEGFILGRASTIM	4	1
PEMBROLIZUMAB	4	1
RUXOLITINIB PHOSPHATE	4	1
SELUMETINIB	4	1
SODIUM PERTECHNETATE TC 99M	4	1
SUNITINIB MALATE	4	1
CADONILIMAB	3	2
CEDIRANIB MALEATE	3	2
BRIVANIB ALANINATE	3	1
DALANTERCEPT	3	1
TREBANANIB	3	1
ONAPRISTONE	2	1
UPROSERTIB	2	1
VISTUSERTIB	2	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 2 predictive associations from 2 curated evidence items; also 1 oncogenic.

Molecular subtype	Therapy	Effect	Level	CIViC
MTOR S2215Y	Sirolimus	Sensitivity/Response	CIViC D	EID1319
TP53 R175H	MDM2 Inhibitor AMGMDS3	Resistance	CIViC D	EID10076